Several possible studies
Story checked
Zolgensma gene therapy link to tumor risk 'will change the calculus' | STAT (opens in a new tab)
statnews.com · 2026-11-06
Short answer
Several possible studiesStudy not confirmed.
Several potential source studies were identified, but no single match could be confirmed. The article's claims remain unverified.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
Help improve NewsLink
Tell us what worked or what needs attention in this check.
The story
Zolgensma gene therapy link to tumor risk 'will change the calculus' | STAT
statnews.com · 2026-11-06
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Multiple potential source studies identified.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
View article claimsSearch result
Several studies could fit.
Several studies match details in the article, but none could be confirmed as its source. The claims have not been assessed against a source study.
Evidence layer
Claim by claim
The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 4Not checkedFor two decades, researchers debated whether adeno-associated viruses used to deliver genes into patients could in certain cases drive tumors, but the article says that debate is now over.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 2 of 4Not checkedA series of cases this year has presented powerful evidence that adeno-associated viruses can cause cancer, according to the story.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 3 of 4Not checkedThe article says the newly confirmed risk will force researchers and families to weigh that risk against the technology’s lifesaving potential and to consider how to design better therapies in the future.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 4 of 4Not checkedSam Mackenzie said the finding 'will change the calculus' for some spinal muscular atrophy patients.View evidenceHide evidence
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Method layer
Study not confirmed.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Crossref, Europe PMC · 15 candidate papers
AAV-CapNet: Multi-Omics Deep Learning with Fourier Enhancement and Cross-Attention for Predicting Infectivity of Known AAV Capsid Variants.
Viruses · 2026 · PubMed
Adeno-associated virus (AAV) gene therapy for spinal muscular atrophy
Journal of the Neurological Sciences · 2023 · Crossref
Novel Technologies and Clinical Breakthroughs: The Evolving Landscape of Gene Therapy in China.
Human Gene Therapy · 2026 · PubMed, Europe PMC
A SynNotch-PiggyBac gene circuit for inflammation-responsive IL-10 delivery in Alzheimer's disease: a hypothesis and design framework.
Frontiers in Aging Neuroscience · 2026 · PubMed
Recombinant Adeno-Associated Virus Serotype 9 Gene Therapy in Spinal Muscular Atrophy
Frontiers in Neurology · 2021 · Crossref